Steel Dynamics, Inc. (NASDAQ:STLD)
Steel Dynamics, Inc. is unique among American steel companies. It is one of the youngest of America’s major steel companies. It quickly grew to become one of the premier carbon steel producers in the United States. Steel Dynamics’ historic growth is a combination of organic capacity greenfield additions and strategic acquisitions. By adding upstream assets that provide raw materials needed to produce high quality steel at each of its mills, and bridging downstream assets that fabricate a variety of high quality steel products, Steel Dynamics has both broadened its product portfolio and expanded its market diversity. As the company’s steelmaking capacity grew and it introduced new products to the market, the company began delivering strong earnings.
Steel Dynamics, Inc. (NASDAQ:STLD)’s Financial Overview
Steel Dynamics, Inc. (NASDAQ) surged 2.21% yesterday to close its trading session at $37. The company has 1 year Price Target of $42.35. Steel Dynamics, Inc. has 52-Week high of $52.1 and 52-Week Low of $28.91. The stock touched its 52-Week High on 52.10 and 52-Week Low on 28.91. The stock traded with the volume of 2.04 Million shares yesterday. The firm shows the market capitalization of $8.55 Billion.
Steel Dynamics, Inc. (NASDAQ) reported its last quarterly earnings on 12/30/2018 where the firm reported its Actual EPS of $1.31/share against the analyst consensus estimate of $1.21/share. The difference between the actual and expected EPS is $0.1 a share with a surprise factor of 8.3%.
The firm is trading with SMA20 of 4.48 Percent, SMA50 of 10.83 Percent and SMA200 of -12.54 percent. Steel Dynamics, Inc. has P/S value of 0.72 while its P/B value stands at 2.15. Similarly, the company has Return on Assets of 14.4 percent, Return on Equity of 28.7 percent and Return on Investment of 13.2 Percent. The company shows Gross Margin and Operating Margin of 19.6 percent and 10.9 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 14 analysts offering 12-month price forecasts for Steel Dynamics Inc have a median target of 43.00, with a high estimate of 51.00 and a low estimate of 32.00. The median estimate represents a +16.22% increase from the last price of 37.00.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)
Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s Financial Outlook
The 10 analysts offering 12-month price forecasts for Amneal Pharmaceuticals Inc have a median target of 18.00, with a high estimate of 35.00 and a low estimate of 15.00. The median estimate represents a +32.35% increase from the last price of 13.60.
Amneal Pharmaceuticals, Inc. is expected* to report earnings on 02/28/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.26. The reported EPS for the same quarter last year was $0.11.
According to Zacks Investment Research, Amneal Pharmaceuticals, Inc. has a Consensus Recommendation of 2.36. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 3.03% and closed its last trading session at $13.6. The company has the market capitalization of $3.97 Billion. The stock has 52-week high of $24.48 and 52-Week low of $11.66. The firm touched its 52-Week high on 24.48 and 52-Week low on 11.66. The company has volume of 644461 shares. The company has a total of 291.61 Million shares outstanding.
Amneal Pharmaceuticals, Inc. (NYSE) in the last quarter reported its actual EPS of $0.28/share where the analyst estimated EPS was $0.28/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.
The company has YTD performance of 0.52 percent. Beta for Amneal Pharmaceuticals, Inc. stands at 1.34 while its ATR (average true range) is 0.66. The company has Weekly Volatility of 4.14%% and Monthly Volatility of 4.61%%.
Amneal Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 8.46%, Distance from 50-Day Simple Moving Average of -4.83 percent and Distance from 200-Day Simple Moving Average of -25.3%.
The Company currently has ROA (Return on Assets) of -10.6 percent, Return on Equity (ROE) of -156 Percent and Return on Investment (ROI) of -43.4% with Gross margin of 39.7 percent and Operating & Profit margin of -27.4% and -23.2% respectively.